Antitumor effect of meclofenamic acid on human androgen-independent prostate cancer: a preclinical evaluation
Authors:
- Daniel A. Montes-GalindoDMDaniel A. Montes-Galindo
- Jose Guzman-EsquivelJose Guzman-Esquivel
- Laura L. Valdez-VelazquezLVLaura L. Valdez-Velazquez
- Luz M. Baltazar-RodriguezLBLuz M. Baltazar-Rodriguez
- Francisco Espinoza-GómezFEFrancisco Espinoza-Gómez
- Augusto Rojas-MartinezARAugusto Rojas-Martinez
- Rocio Ortiz-LopezRORocio Ortiz-Lopez
- Rafael Gonzalez-AlvarezRGRafael Gonzalez-Alvarez
- 10 June 2011
- journal article
- research article
- Published by Springer Nature in International Urology and Nephrology
- Vol. 44 (2) , 471-477
Abstract
Prostate cancer is a worldwide public health problem and its treatment continues to be a therapeutic challenge especially in patients with metastatic androgen-independent cancer. Inflammation is a process that has been involved in the origin of this cancer and its inhibition has been postulated as a prophylactic and therapeutic strategy. The present study evaluated two non-steroidal anti-inflammatory drugs (meclofenamic acid and mefenamic acid) that have been studied very little in regard to cancer treatment. In vitro, the cytotoxic effects of meclofenamic acid and mefenamic acid were determined in human prostate cancer cell lines (LNCaP: androgen-dependent; and PC3: androgen-independent). In vivo trials were divided into two phases; meclofenamic acid toxicity was initially determined at different doses (0, 5, 10 and 20 mg/kg/day/25 days) in BALB/c mice, after which a trial using non-toxic doses was carried out to evaluate the antitumor efficacy of the drug in a PC3/nude-mouse model of human androgen-independent prostate cancer. In vitro trials showed that only meclofenamic acid is highly cytotoxic in neoplastic prostate cells. The 5 and 10 mg/kg/day/25 day doses did not cause relevant toxicity in the BALB/c mouse trial, and so both doses were used in the nude-mouse model of cancer trial. This latter trial showed that meclofenamic acid significantly reduces tumor growth, prolongs survival, and is even capable of generating total tumor regression in up to 25% of mice treated at high dose. Meclofenamic acid was shown to be a potential antineoplastic agent for both androgen-dependent and androgen-independent prostate cancer.Keywords
This publication has 32 references indexed in Scilit:
- Use of Aspirin and Other Nonsteroidal Antiinflammatory Medications in Relation to Prostate Cancer RiskAmerican Journal of Epidemiology, 2010
- Effective antiproliferative effect of meloxicam on prostate cancer cells: Development of a new controlled release systemInternational Journal of Pharmaceutics, 2010
- Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statementThe Lancet Oncology, 2009
- AKR1C3 as a potential target for the inhibitory effect of dietary flavonoidsChemico-Biological Interactions, 2009
- Guía de la EAU para el Cáncer de PróstataActas Urológicas Españolas, 2009
- Celecoxib‐induced growth inhibition in SW480 colon cancer cells is associated with activation of protein kinase GMolecular Carcinogenesis, 2007
- Molecular targets of nitric-oxide-donating aspirin in cancerBiochemical Society Transactions, 2005
- Role of COX-Independent Targets of NSAIDs and Related Compounds in Cancer Prevention and Treatment2003
- Comparative toxicity of non-steroidal anti-inflammatory agentsPharmacology & Therapeutics, 1994
- A single and multiple dose pharmacokinetic and metabolism study of meclofenamate sodiumBiopharmaceutics & Drug Disposition, 1990